BRPI0616111B8 - derivados de carboxamida, composição farmacêutica, uso dos mesmos e combinação - Google Patents

derivados de carboxamida, composição farmacêutica, uso dos mesmos e combinação

Info

Publication number
BRPI0616111B8
BRPI0616111B8 BRPI0616111A BRPI0616111A BRPI0616111B8 BR PI0616111 B8 BRPI0616111 B8 BR PI0616111B8 BR PI0616111 A BRPI0616111 A BR PI0616111A BR PI0616111 A BRPI0616111 A BR PI0616111A BR PI0616111 B8 BRPI0616111 B8 BR PI0616111B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
combination
carboxamide derivatives
intermediates
carboxamide
Prior art date
Application number
BRPI0616111A
Other languages
English (en)
Inventor
Wood Anthony
Anne Louise Watson Christine
Alan Glossop Paul
Sinclair Strang Ross
John Mantell Simon
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of BRPI0616111A2 publication Critical patent/BRPI0616111A2/pt
Publication of BRPI0616111B1 publication Critical patent/BRPI0616111B1/pt
Publication of BRPI0616111B8 publication Critical patent/BRPI0616111B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

composto de carboxamida, seu uso, combinações e intermediários. a invenção refere-se a compostos da fómula processos e intermediários para a sua preparação, seu uso como antagonistas muscarínicos e composição farmacêutica contendo-os.
BRPI0616111A 2005-09-21 2006-09-01 derivados de carboxamida, composição farmacêutica, uso dos mesmos e combinação BRPI0616111B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US71946805P 2005-09-21 2005-09-21
US71946705P 2005-09-21 2005-09-21
US71947705P 2005-09-21 2005-09-21
US60/719,477 2005-09-21
US60/719,467 2005-09-21
US60/719,468 2005-09-21
PCT/IB2006/002727 WO2007034325A1 (en) 2005-09-21 2006-09-01 Carboxamide derivatives as muscarinic receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0616111A2 BRPI0616111A2 (pt) 2011-06-07
BRPI0616111B1 BRPI0616111B1 (pt) 2019-10-08
BRPI0616111B8 true BRPI0616111B8 (pt) 2021-05-25

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616111A BRPI0616111B8 (pt) 2005-09-21 2006-09-01 derivados de carboxamida, composição farmacêutica, uso dos mesmos e combinação

Country Status (43)

Country Link
US (3) US7772223B2 (pt)
EP (1) EP1928821B1 (pt)
JP (1) JP4221447B1 (pt)
KR (1) KR100976909B1 (pt)
CN (1) CN101268046B (pt)
AP (1) AP1983A (pt)
AR (1) AR055171A1 (pt)
AT (1) ATE420069T1 (pt)
AU (1) AU2006293618B9 (pt)
BR (1) BRPI0616111B8 (pt)
CA (1) CA2623332C (pt)
CR (2) CR9814A (pt)
CU (1) CU20100115A7 (pt)
CY (1) CY1108880T1 (pt)
DE (1) DE602006004768D1 (pt)
DK (1) DK1928821T3 (pt)
DO (1) DOP2006000202A (pt)
EA (1) EA013083B1 (pt)
EC (1) ECSP088265A (pt)
ES (1) ES2318794T3 (pt)
GE (1) GEP20104880B (pt)
GT (1) GT200600422A (pt)
HK (1) HK1117163A1 (pt)
HN (1) HN2006032615A (pt)
HR (1) HRP20090127T3 (pt)
IL (1) IL189453A (pt)
MA (1) MA29839B1 (pt)
ME (1) ME01106B (pt)
MX (1) MX2008002805A (pt)
MY (1) MY143581A (pt)
NL (1) NL2000241C2 (pt)
NO (1) NO340975B1 (pt)
NZ (1) NZ566023A (pt)
PE (1) PE20070460A1 (pt)
PL (1) PL1928821T3 (pt)
PT (1) PT1928821E (pt)
RS (2) RS51680B (pt)
SI (1) SI1928821T1 (pt)
TN (1) TNSN08137A1 (pt)
TW (1) TWI322143B (pt)
UY (1) UY29798A1 (pt)
WO (1) WO2007034325A1 (pt)
ZA (1) ZA200801432B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
EP2066626B1 (en) * 2006-09-22 2010-03-17 Pfizer Limited Azetidine derivatives as muscarinic receptor antagonists
ATE512132T1 (de) * 2007-03-16 2011-06-15 Pfizer Ltd Hydrochloridsalz von 5-ä3-(3- hydroxyphenoxy)azetidin-1-ylü-5-methyl-2,2- diphenylhexanamid
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN103201244B (zh) * 2010-08-26 2015-06-17 阿尔比马尔公司 用于制备1-溴代-2-(环丙基甲氧基)-5-氟代-4-甲氧基苯的方法
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) * 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
EP3596046A1 (en) 2017-03-15 2020-01-22 Mylan Laboratories Ltd. Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
PL3691620T3 (pl) 2017-10-05 2022-11-21 Fulcrum Therapeutics, Inc. Inhibitory kinazy p38 zmniejszają poziom ekspresji genu dux4 i dalszych genów do leczenia fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
EP3990091A4 (en) * 2019-06-25 2023-07-12 Mylan Laboratories Ltd. PROCESSES AND INTERMEDIATE PRODUCTS FOR THE PREPARATION OF HYDROCHLORIDE SALT OF 5-[3-(3-HYDROXYPHENOXY)AZETIDIN-1-YL]-5-METHYL-2,2-DIPHENYLHEXANAMIDE
WO2021260441A1 (en) 2020-06-26 2021-12-30 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
WO2023049696A1 (en) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Methylation of 2-chloro-6-fluorophenol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6071950A (en) * 1996-12-02 2000-06-06 Kyorin Pharmaceutical Co., Ltd. N-substituted pyrrolidine derivatives and process for preparing the same
EP0848964B1 (de) * 1996-12-17 2007-07-25 Filtertek B.V. Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CA2470956C (en) 2001-12-20 2011-08-02 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (en) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
MXPA05002839A (es) 2002-09-17 2005-05-27 Actelion Pharmaceuticals Ltd Derivados de 1-piridin-4-il-urea.

Also Published As

Publication number Publication date
TNSN08137A1 (fr) 2009-07-14
AU2006293618A1 (en) 2007-03-29
DOP2006000202A (es) 2007-04-15
EP1928821A1 (en) 2008-06-11
ME01106B (me) 2013-03-20
ECSP088265A (es) 2008-04-28
EP1928821B1 (en) 2009-01-07
CN101268046A (zh) 2008-09-17
CR20130209A (es) 2013-09-19
GEP20104880B (en) 2010-01-11
EA013083B1 (ru) 2010-02-26
MX2008002805A (es) 2008-04-07
NO340975B1 (no) 2017-07-31
UY29798A1 (es) 2007-04-30
US20100029720A1 (en) 2010-02-04
EA200800540A1 (ru) 2008-08-29
US7772223B2 (en) 2010-08-10
TW200745024A (en) 2007-12-16
CR9814A (es) 2008-04-16
KR100976909B1 (ko) 2010-08-18
AP1983A (en) 2009-03-24
AR055171A1 (es) 2007-08-08
PL1928821T3 (pl) 2009-06-30
CY1108880T1 (el) 2014-07-02
IL189453A0 (en) 2008-08-07
US8268881B2 (en) 2012-09-18
HRP20090127T3 (en) 2009-06-30
CU23910B1 (pt) 2013-06-29
PE20070460A1 (es) 2007-05-14
JP2009508933A (ja) 2009-03-05
DE602006004768D1 (de) 2009-02-26
NO20081001L (no) 2008-03-25
ES2318794T3 (es) 2009-05-01
CU20100115A7 (es) 2011-10-14
AU2006293618B9 (en) 2009-10-29
CA2623332C (en) 2012-05-01
NZ566023A (en) 2010-02-26
BRPI0616111B1 (pt) 2019-10-08
SI1928821T1 (sl) 2009-04-30
US20070105831A1 (en) 2007-05-10
WO2007034325A1 (en) 2007-03-29
PT1928821E (pt) 2009-03-10
RS50855B (sr) 2010-08-31
TWI322143B (en) 2010-03-21
US20110251164A1 (en) 2011-10-13
RS51680B (en) 2011-10-31
DK1928821T3 (da) 2009-03-16
MY143581A (en) 2011-05-31
CN101268046B (zh) 2012-07-25
MA29839B1 (fr) 2008-10-03
JP4221447B1 (ja) 2009-02-12
CA2623332A1 (en) 2007-03-29
HK1117163A1 (en) 2009-01-09
HN2006032615A (es) 2010-10-04
AU2006293618B2 (en) 2009-10-08
US8486992B2 (en) 2013-07-16
IL189453A (en) 2014-06-30
NL2000241C2 (nl) 2009-01-05
NL2000241A1 (nl) 2007-03-22
GT200600422A (es) 2007-05-28
BRPI0616111A2 (pt) 2011-06-07
RS20080119A (en) 2009-05-06
KR20080037103A (ko) 2008-04-29
ZA200801432B (en) 2009-07-29
ATE420069T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
BRPI0616111B8 (pt) derivados de carboxamida, composição farmacêutica, uso dos mesmos e combinação
BRPI0707704A8 (pt) derivados de antranilamida / 2-amino-heteroareno carboxamida
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
BRPI0715579A2 (pt) "composto, composição farmacêutica e uso de um composto"
BRPI0915084B8 (pt) composto, e, composição farmacêutica
BRPI0514731A (pt) derivados de pirimidina
DOP2011000176A (es) Compuestos organicos
BR112012011793A2 (pt) "acrilamidas heterocíclicas e seu uso como farmacêuticos"
BRPI0607545A2 (pt) composto, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
JO2770B1 (en) Organic compounds
BRPI0606964A2 (pt) pirrolidinas e piperidinas derivadas do acetileno para uso como antagonistas de mglur5
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
EA200700166A1 (ru) 4-замещённые производные хинолина, способ получения и промежуточные вещества для их приготовления и содержащие их фармацевтические композиции
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
BRPI0511999A (pt) compostos como antagonistas de ccr5
UY31016A1 (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
UY30356A1 (es) Derivados de 3-halo-n-(2.(4-fluorofenil)-4-oxobutil)-n-metil-5-(trifluorometil)benzamida y composiciones de los mismos.
DE602007005387D1 (de) Ptors
BRPI0520806A2 (pt) derivados pirrólicos, processos para a preparação de compostos, seu uso e composição farmacêutica que os contém
WO2009034432A8 (en) Novel compounds active as muscarinic receptor antagonists
EA200701180A1 (ru) Способ и промежуточные продукты для получения канфосфамида и его солей, фармацевтические композиции, содержащие некоторые промежуточные продукты и их применение в качестве противораковых средств
WO2007034254A8 (en) Amino-alkyl-amide derivatives as ccr3 receptor ligands
BRPI0513386A (pt) inibidores de reabsorção de norepinefrina de quinoxalinona para o tratamento de distúrbios do sistema nervoso central
BRPI0816950A2 (pt) Compostos, medicamento, composição farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/09/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF